{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T18:27:44Z","timestamp":1676140064067},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2008,7,6]],"date-time":"2008-07-06T00:00:00Z","timestamp":1215302400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1007\/s00108-008-2057-4","type":"journal-article","created":{"date-parts":[[2008,7,4]],"date-time":"2008-07-04T07:42:19Z","timestamp":1215157339000},"page":"929-937","source":"Crossref","is-referenced-by-count":1,"title":["Therapie b\u00f6sartiger H\u00e4moblastosen mit monoklonalen Antik\u00f6rpern"],"prefix":"10.1007","volume":"49","author":[{"given":"G.","family":"Held","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pfreundschuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,7,6]]},"reference":[{"key":"2057_CR1","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.2003.06.012","volume":"21","author":"Bannerji","year":"2003","unstructured":"Bannerji R, Kitada S, Flinn IW et al. (2003) Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 21: 1466\u20131471","journal-title":"J Clin Oncol"},{"key":"2057_CR2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1182\/blood.V110.11.2557.2557","volume":"110","author":"Bargou","year":"2007","unstructured":"Bargou RC, Kufer P, Goebeler M et al. (2007) The anti-CD19 bispecific T-cell engager (BiTE) MT103 (MEDI-538) induces dose-dependent complete and partial remissions in relapsed non-Hodgin lymphoma: Phase I study MT103\u2013104. Blood 110: 753","journal-title":"Blood"},{"key":"2057_CR3","first-page":"8","volume":"108","author":"Burnett","year":"2006","unstructured":"Burnett AK, Kell WJ, Goldstone AH et al. (2006) The addition of gemtuzumab ozagamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1115 patientsn in the MRC AML15 trial. Blood 108: 8","journal-title":"Blood"},{"key":"2057_CR4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","volume":"101","author":"Byrd","year":"2003","unstructured":"Byrd JC, Peterson BL, Morrison VA et al. (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101: 6\u201314","journal-title":"Blood"},{"key":"2057_CR5","first-page":"1927","volume":"92","author":"Coiffier","year":"1998","unstructured":"Coiffier B, Haioun C, Ketterer N et al. (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92: 1927\u20131932","journal-title":"Blood"},{"key":"2057_CR6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235\u2013242","journal-title":"N Engl J Med"},{"key":"2057_CR7","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"Dohner","year":"2000","unstructured":"Dohner H, Stilgenbauer S, Benner A et al. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343: 1910\u20131916","journal-title":"N Engl J Med"},{"key":"2057_CR8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/cncr.11551","volume":"98","author":"Ferrajoli","year":"2003","unstructured":"Ferrajoli A, O\u2019Brien SM, Cortes JE et al. (2003) Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 98: 773\u2013778","journal-title":"Cancer"},{"key":"2057_CR9","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","unstructured":"Forstpointner R, Unterhalt M, Dreyling M et al. (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108: 4003\u20134008","journal-title":"Blood"},{"key":"2057_CR10","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.beha.2006.06.008","volume":"19","author":"Gokbuget","year":"2006","unstructured":"Gokbuget N, Hoelzer D (2006) Novel antibody-based therapy for acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 19: 701\u2013713","journal-title":"Best Pract Res Clin Haematol"},{"key":"2057_CR11","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.2005.12.171","volume":"23","author":"Gordan","year":"2005","unstructured":"Gordan LN, Grow WB, Pusateri A et al. (2005) Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 23: 1096\u20131102","journal-title":"J Clin Oncol"},{"key":"2057_CR12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/blood.V110.11.643.643","volume":"110","author":"Hagenbeek","year":"2007","unstructured":"Hagenbeek A, Bischof-Delaloye F, Radford JA et al. (2007) 90Y-ibritumomab tiuxetan (Zevalin) consolidation of first remission in advanced stage follicular non-Hodgkin lymphoma: First results of the international randomized phase 3 first-line indolent trial (FIt) in 414 patients. Blood 110: 198","journal-title":"Blood"},{"key":"2057_CR13","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"Herold","year":"2007","unstructured":"Herold M, Haas A, Srock S et al. (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25: 1986\u20131992","journal-title":"J Clin Oncol"},{"key":"2057_CR14","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M et al. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106: 3725\u20133732","journal-title":"Blood"},{"key":"2057_CR15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"Kaminski","year":"2005","unstructured":"Kaminski MS, Tuck M, Estes J et al. (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352: 441\u2013449","journal-title":"N Engl J Med"},{"key":"2057_CR16","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1200\/jco.2008.26.15_suppl.8502","volume":"26","author":"Kraeber-Bodere","year":"2008","unstructured":"Kraeber-Bodere F, Morschhauser F, Huglo D et al. (2008) Fractionated radioimmunotherapy in NHL with DOTA-conjugate humanized anti-CD22 IgG, epratuzumab: Results at high cumulative doses of 90Y. J Clin Oncol 26: 8502","journal-title":"J Clin Oncol"},{"key":"2057_CR17","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E et al. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23: 1984\u20131992","journal-title":"J Clin Oncol"},{"key":"2057_CR18","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1200\/JCO.2005.13.821","volume":"23","author":"Leonard","year":"2005","unstructured":"Leonard JP, Coleman M, Ketas J et al. (2005) Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin\u2019s lymphoma. J Clin Oncol 23: 5044\u20135051","journal-title":"J Clin Oncol"},{"key":"2057_CR19","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2003.01.082","volume":"21","author":"Leonard","year":"2003","unstructured":"Leonard JP, Coleman M, Ketas JC et al. (2003) Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol 21: 3051\u20133059","journal-title":"J Clin Oncol"},{"key":"2057_CR20","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","volume":"100","author":"Lundin","year":"2002","unstructured":"Lundin J, Kimby E, Bjorkholm M et al. (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100: 768\u2013773","journal-title":"Blood"},{"key":"2057_CR21","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A et al. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105: 1417\u20131423","journal-title":"Blood"},{"key":"2057_CR22","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825\u20132833","journal-title":"J Clin Oncol"},{"key":"2057_CR23","first-page":"454","volume":"26","author":"Micallelef","year":"2008","unstructured":"Micallelef IN, Maurer MJ, Nikcevich DA et al. (2008) A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP). J Clin Oncol 26: 454","journal-title":"J Clin Oncol"},{"key":"2057_CR24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2007-01-068056","volume":"110","author":"Morschhauser","year":"2007","unstructured":"Morschhauser F, Illidge T, Huglo D et al. (2007) Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 110: 54\u201358","journal-title":"Blood"},{"key":"2057_CR25","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood-2007-03-080010","volume":"111","author":"O","year":"2008","unstructured":"O\u2019Brien S, Ravandi F, Riehl T et al. (2008) Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 111: 1816\u20131819","journal-title":"Blood"},{"key":"2057_CR26","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","volume":"19","author":"O","year":"2001","unstructured":"O\u2019Brien SM, Kantarjian H, Thomas DA et al. (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19: 2165\u20132170","journal-title":"J Clin Oncol"},{"key":"2057_CR27","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","volume":"15","author":"Osterborg","year":"1997","unstructured":"Osterborg A, Dyer MJ, Bunjes D et al. (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15: 1567\u20131574","journal-title":"J Clin Oncol"},{"key":"2057_CR28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M et al. (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9: 105\u2013116","journal-title":"Lancet Oncol"},{"key":"2057_CR29","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","volume":"104","author":"Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Trumper L, Kloess M et al. (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104: 634\u2013641","journal-title":"Blood"},{"key":"2057_CR30","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A et al. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7: 379\u2013391","journal-title":"Lancet Oncol"},{"key":"2057_CR31","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/jco.2008.26.15_suppl.8508","volume":"26","author":"Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Zeynalova S, Poeschel V et al. (2008) Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma after dose-dens3 rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grad Non-Hodgkin Lymphoma Study Group (DSHNHL). J Clin Oncol 26: 456","journal-title":"J Clin Oncol"},{"key":"2057_CR32","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/jcp.47.4.313","volume":"47","author":"Salisbury","year":"1994","unstructured":"Salisbury JR, Rapson NT, Codd JD et al. (1994) Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin\u2019s lymphomas. J Clin Pathol 47: 313\u2013317","journal-title":"J Clin Pathol"},{"key":"2057_CR33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.V104.11.160.160","volume":"104","author":"Salles","year":"2004","unstructured":"Salles G, Foussard C, Nicolas M (2004) Rituximab added to aIFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: First analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. Blood 104: 49","journal-title":"Blood"},{"key":"2057_CR34","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V110.11.3114.3114","volume":"110","author":"Sayala","year":"2007","unstructured":"Sayala HA, Moreton P, Kennedy B et al. (2007) Eradication of minimal residual disease with alemtuzumab in chronic lymphocytic leukemia is associated with prolonged survival an is an appropriate therapeutic endpoint for relapsed CLL. Blood 110: 916","journal-title":"Blood"},{"key":"2057_CR35","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","volume":"99","author":"Schulz","year":"2007","unstructured":"Schulz H, Bohlius JF, Trelle S et al. (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99: 706\u2013714","journal-title":"J Natl Cancer Inst"},{"key":"2057_CR36","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","volume":"93","author":"Sievers","year":"1999","unstructured":"Sievers EL, Appelbaum FR, Spielberger RT et al. (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93: 3678\u20133684","journal-title":"Blood"},{"key":"2057_CR37","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM200208083470619","volume":"347","author":"Stilgenbauer","year":"2002","unstructured":"Stilgenbauer S, Dohner H (2002) Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 347: 452\u2013453","journal-title":"N Engl J Med"},{"key":"2057_CR38","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1182\/blood.V110.11.3120.3120","volume":"110","author":"Stilgenbauer","year":"2007","unstructured":"Stilgenbauer S, Winkler D, B\u00fchler D et al. (2007) Subcutaneous alemtuzumab (MabCampath) in fuldarabine-refractory CLL (CLL2H trial of the GCLLSG). Blood 110: 918","journal-title":"Blood"},{"key":"2057_CR39","unstructured":"Stone RM (2004) AML: Current landscape and future directions 98\u2013103"},{"key":"2057_CR40","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2006.05.6291","volume":"24","author":"Strauss","year":"2006","unstructured":"Strauss SJ, Morschhauser F, Rech J et al. (2006) Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin\u2019s lymphoma. J Clin Oncol 24: 3880\u20133886","journal-title":"J Clin Oncol"},{"key":"2057_CR41","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"The","year":"1993","unstructured":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 329: 987\u2013994","journal-title":"N Engl J Med"},{"key":"2057_CR42","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"van","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE et al. (2006) Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108: 3295\u20133301","journal-title":"Blood"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-008-2057-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-008-2057-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-008-2057-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T20:56:53Z","timestamp":1588798613000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-008-2057-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,6]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["2057"],"URL":"https:\/\/doi.org\/10.1007\/s00108-008-2057-4","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,6]]}}}